Patents Assigned to ZymoGenetics, Inc.
  • Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists
    Patent number: 7723048
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: May 25, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine Bilsborough, Jane A. Gross
  • Cytokine receptor
    Patent number: 7723298
    Abstract: Novel methods are disclosed for forming a heterodimeric receptor complex with IL-28R and CRF2-4. The methods may be used for detecting and treating viral infections in in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: October 9, 2006
    Date of Patent: May 25, 2010
    Assignee: ZymoGenetics, Inc.
    Inventor: Wenfeng Xu
  • Anti-IL-TIF antibodies and methods of using in inflammation
    Patent number: 7718172
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: May 18, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • ANTI-IL-20, ANTI-IL-22 AND ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20100111960
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Application
    Filed: October 9, 2009
    Publication date: May 6, 2010
    Applicant: ZymoGenetics, Inc.
    Inventor: Wenfeng Xu
  • SOLUBLE IL-17RCX4 AND METHODS OF USING IN INFLAMMATION
    Publication number: 20100113748
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
    Type: Application
    Filed: October 15, 2009
    Publication date: May 6, 2010
    Applicant: Zymogenetics, Inc.
    Inventors: Rolf E. Kuestner, Zeren Gao, Steven D. Levin, Mark W. Rixon
  • ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION
    Publication number: 20100111948
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
    Type: Application
    Filed: October 16, 2009
    Publication date: May 6, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
  • Methods of using soluble heterodimeric cytokine receptor
    Patent number: 7704950
    Abstract: A soluble receptor that binds to IL-20 having two polypeptide subunits, IL-22R and IL-20RB. The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
    Type: Grant
    Filed: March 26, 2007
    Date of Patent: April 27, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Julia E. Novak, Donald C. Foster, Wenfeng Xu, Stephen R. Jaspers
  • HUMAN CYTOKINE RECEPTOR
    Publication number: 20100099850
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Application
    Filed: October 2, 2009
    Publication date: April 22, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Human zven polynucleotides
    Patent number: 7691610
    Abstract: The present invention provides a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis. The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes. The invention also provides methods for using the antibodies to detect the presence of the protein with antibodies and methods for using the polynucleotides to detect the presence of Zven RNA.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 6, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Paul O. Sheppard, Paul D. Bishop
  • Human Zven polypeptides
    Patent number: 7691585
    Abstract: The present invention provides polypeptides and compositions comprising amino acid residues 23 to 108 of SEQ ID NO: 2, polypeptides and compositions comprising amino acid residues 28 to 108 of SEQ ID NO: 2, including affinity tags and the like, useful for stimulating gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 6, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Paul O. Sheppard, Paul D. Bishop
  • Growth factor homolog zvegf3
    Patent number: 7691981
    Abstract: Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptides are also disclosed. The polypeptides, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: April 6, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker
  • ANTIBODIES TO MAMMALIAN CYTOKINE-LIKE FACTOR 7
    Publication number: 20100076179
    Abstract: Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies.
    Type: Application
    Filed: September 16, 2009
    Publication date: March 25, 2010
    Applicant: ZymoGenetics, Inc.
    Inventors: Scott R. Presnell, Teresa Gilbert
  • Anti-IL-TIF antibodies
    Patent number: 7674461
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: March 9, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Wenfeng Xu, Wayne Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • MAMMALIAN ZCYTOR 11
    Publication number: 20100055778
    Abstract: Novel receptor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides comprise an extracellular domain of a cell-surface receptor that is expressed in pancreas, small intestine, colon and thymus. The polypeptides may be used within methods for detecting ligands that promote the proliferation and/or differentiation of these organs.
    Type: Application
    Filed: September 10, 2009
    Publication date: March 4, 2010
    Applicant: ZymoGenetics, Inc
    Inventors: Si Lok, Robyn L. Adams, Anna C. Jelmberg, Theodore E. Whitmore, Theresa M. Farrah
  • Methods of increasing cartilage deposition using FGF homologs
    Patent number: 7671020
    Abstract: The present invention relates to methods of using zFGF5 compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage injuries and defects. In addition, methods for treating neurological disorders, such as stroke, are disclosed, and methods for using zFGF5 compositions to stimulate growth of cells associated with neurological injury and disease are disclosed.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: March 2, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Theresa A. Deisher, Darrell C. Conklin
  • Antibodies to Zcytor 16
    Patent number: 7667000
    Abstract: Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor16.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: February 23, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Scott R. Presnell, Wenfeng Xu, Wayne Kindsvogel, Zhi Chen
  • Method of using Zven antibodies
    Patent number: 7662641
    Abstract: The present invention provides novel uses two members of a new family of human proteins, designated as “Zven,” as agents that stimulate gastrointestinal contractility, gastric emptying, intestinal transit, and treating gastroparesis The Zven1 gene, which resides in human chromosome 3p21.1-3p14.3, is expressed in testicular tissue and peripheral blood lymphocytes. The invention also provides methods for using the antibodies to detect the presence of the protein with antibodies and methods for using the polynucleotides to detect the presence of Zven RNA.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: February 16, 2010
    Assignee: Zymogenetics, Inc.
    Inventors: Paul O. Sheppard, Paul D. Bishop
  • Method of inhibiting the activity of growth factor homolog ZVEGF3
    Patent number: 7658920
    Abstract: Polypeptide growth factor ZVEGF3, methods of making it, polynucleotides encoding it, antibodies that bind to it, and methods of using them are disclosed. The polypeptide comprises an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residues 235-345 of SEQ ID NO:2. Multimers of the polypeptide are also disclosed. The polypeptide, multimeric proteins, and polynucleotides can be used in the study and regulation of cell and tissue development, as components of cell culture media, and as diagnostic agents. The antibodies may be used to inhibit cell growth.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: February 9, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Zeren Gao, Charles E. Hart, Christopher S. Piddington, Paul O. Sheppard, Kimberly E. Shoemaker
  • ZSIG33-like polynucleotides
    Patent number: 7655447
    Abstract: The present invention relates to polynucleotide related to the zsig33 peptide, including agonists, antagonists, and antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: February 2, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Paul O. Sheppard
  • Cytokine zalpha11 ligand polynucleotides
    Patent number: RE41129
    Abstract: The present invention relates to zalpha11 Ligand polynucleotide and polypeptide molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used within methods for stimulating the proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: February 2, 2006
    Date of Patent: February 16, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond